Subsequently, AUY922 was again reported to be associated with severe adverse effects such as diarrhea, nausea, and decreased appetite in the treatment of EGFR-mutant NSCLC patients [27]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.